TYRA - Tyra Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$50.50
DETAILS
HIGH:
$59.00
LOW:
$42.00
MEDIAN:
$51.50
CONSENSUS:
$50.50
UPSIDE:
55.53%
About Tyra Biosciences, Inc. (https://www.tyra.bio)
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Todd Harris | Co-Founder, CEO, President & Director | 1979 | $998,960 USD |
| Douglas Warner | Chief Medical Officer | 1972 | $764,683 USD |
| Alan Fuhrman | Chief Financial Officer | 1957 | $763,093 USD |
| Daniel Bensen | Co-Founder & Chief Discovery Officer | 1975 | $737,643 USD |
| Ali D. Fawaz | General Counsel & Secretary | – | $629,230 USD |
| Bhavesh Ashar | Chief Operating Officer | 1969 | $551,017 USD |
| Ronald V. Swanson | Chief Scientific Officer | 1963 | $536,188 USD |
| Erik Goluboff | Senior Vice President of Clinical Development | – | – |
| Julia Rueb | VP of Finance & Principal Accounting Officer | 1986 | – |
| Liz Pagano | Chief Human Resources Officer | – | – |
| Ralph William Charlton | Senior Vice President of Clinical Development | 1971 | – |
| Robert L. Hudkins | Chief Technology Officer | 1955 | – |
| Sarah Honig | Senior Vice President of Corporate Development & Strategy | – | – |